ArticleRheumatology (Oxford, England)2026
Development of structural damage in the spine in patients with PsA: findings from a longitudinal cohort study.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesThis study aimed to examine associations between disease activity/severity markers across multiple PsA domains and structural damage development in the spine in a large longitudinal cohort.
methodsWe analysed patients from a prospective longitudinal PsA cohort and evaluated structural damage in the spine by assessing the development of new syndesmophytes (a binary outcome) on radiographs of the cervical and lumbar spine. We used Cox regression to examine the association between syndesmophyte development and disease activity and severity variables, including nail involvement, PASI, swollen joint count, SPARCC enthesitis score, dactylitis, cDAPSA, modified Steinbrocker score, radiographic sacroiliitis score (range 0-8), BASDAI, ESR and CRP. Separate multivariable models were conducted and adjusted for age, sex, PsA duration, BMI, smoking status, decade of observation, HLA-B*27, HLA-A*29, NSAID use and, where applicable, radiographic sacroiliitis score and b/tsDMARD use.
resultsAmong 1584 PsA patients (median age 45), 218 (13.8%) had syndesmophytes at baseline (clinic entry). Median follow-up was 8.5 years [IQR: 4.4-14.3]. Among 922 patients without baseline syndesmophytes who underwent repeat radiographs, 166 (18.0%) developed new syndesmophytes, with a median time to development of 5.8 years [IQR: 2.4-9.9]. The incidence of new syndesmophytes appeared to decline in more recent calendar years. In multivariable models, higher ESR (HR 1.02, 95% CI 1.01-1.03) and higher radiographic sacroiliitis score (HR 1.19, 95% CI 1.07-1.32) were associated with syndesmophyte development.
conclusionSyndesmophytes developed in approximately one-fifth of patients with PsA during long-term follow-up. Systemic inflammation and radiographic sacroiliitis are major, independent predictors of spinal structural damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.